As part of its Critical Path Initiative, FDA recognizes the need for collaborations established under the terms and conditions of a cooperative agreement to facilitate Critical Path Public-Private Partnerships / Consortia activities.

This includes developing innovative, collaborative projects

credit:

in research, education, and outreach for fostering medical product innovation, enabling the acceleration of medical product development, manufacturing, and translational therapeutics, and enhancing medical product safety.